June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Association of HLA-B*44:03 with Stevens-Johnson syndrome in Brazilian patients
Author Affiliations & Notes
  • Tais Hitomi Wakamatsu
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Mayumi Ueta
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
    Research Center for Inflammation and Regenerative Medicine, Doshisha University,, Kyoto, Japan
  • Renata Ruoco Loureiro
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Kárita Antunes Costa
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Juliana M F Sallum
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Chie Sotozono
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Shigeru Kinoshita
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • José Alvaro Pereira Gomes
    Ophthalmology, Federal University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships Tais Wakamatsu, None; Mayumi Ueta, None; Renata Loureiro, None; Kárita Costa, None; Juliana Sallum, None; Chie Sotozono, None; Shigeru Kinoshita, None; José Gomes, Allergan (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5993. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tais Hitomi Wakamatsu, Mayumi Ueta, Renata Ruoco Loureiro, Kárita Antunes Costa, Juliana M F Sallum, Chie Sotozono, Shigeru Kinoshita, José Alvaro Pereira Gomes; Association of HLA-B*44:03 with Stevens-Johnson syndrome in Brazilian patients. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5993.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the etiologic factors that have been implicated as causes of Stevens-Johnson syndrome and the prevalent HLA class I - B gene.

Methods: Seventy-four patients with SJS/NET with severe ocular surface complications (41 females; 32 males; age range 7 months to 70 years; mean age, 36,01 ± 15,42) recruited at Federal University of São Paulo were enrolled in this study. The age range at onset was 3 to 69 years and the mean age at onset, 23,05 ± 15,85. The study ethnicity was variable: pardo, n = 38 (51%); white, n = 30 (40%); black, n = 4 (6%); Indian plus white, n = 2 (3%). Healthy Brazilian volunteers (n=134) served as the controls. We performed polymerase chain reaction assay followed by hybridization with sequence-specific oligonucleotide probe using commercial bead-based typing kits.

Results: Drugs are most often implicated as the etiology in adults. Cold medicines including non-steroidal anti-inflammatory drugs, multi-ingredient cold medications and anti-pyretic medicines are reported to be important inciting causative factors. In our study this group of medication was also the main SJS causative drug totalizing 53% of the patients. The second most important group of medication was the anti-convulsant (15%, including Phenobarbital, n = 5; Carbamazepim, n = 3 and Phenytoin, n = 3). The etiology of SJS in five patients was unknown. HLA class I B analysis showed HLA-B44:03 as the most prevalent allele, with a gene frequency of 19/148 (12.8%) and a carrier frequency of 18/74 (24,3%). There was a significant association between patients with SJS/NET and HLA-B*44:03 (carrier frequency: p = 0.0224, OR = 2.550, gene frequency: p=0.0167, OR = 2.484). Considering all patients with a HLA-B*44:03 allele we could observed that 66.67% had SJS/NET caused by cold medicine and 5.55% caused by anti-convulsant.

Conclusions: We found that HLA-B*44:03 was significantly associated with SJS/NET and the main causative drug of these diseases was cold medicine.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×